Appendix 4c – q4 fy25 quarterly cash flow report

Highlights granted u.s. fda fast track designation for ath434 to treat multiple system atrophy (msa) reported positive topline data from open-label phase 2 clinical trial of ath434 in msa presented additional analyses from the ath434-201 trial demonstrating continued robust efficacy for the treatment of msa cash balance on 30 june 2025 of a$40.66m melbourne, australia and san francisco, july 30, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its appendix 4c quarterly cash flow report and update on company activities for the quarter ending 30 june 2025 (q4 fy25). “u.s. fda fast track designation for ath434 in msa was the highlight of the recent quarter that also featured additional positive clinical data from our phase 2 double-blind trial,” said david stamler, m.d.
MSA Ratings Summary
MSA Quant Ranking